Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesAberrant fatty acid-binding protein-7 gene expression in cutaneous malignant melanoma
Journal of Investigative Dermatology, 07/14/09
Goto Y et al. - In a trial to assess the role of fatty acid-binding protein-7 (FABP7) in tumor progression, it seems that assessment of pts' blood showed that FABP7(+) circulating tumor cells (CTCs) decreased with disease progression. FABP7 may function as a tumor progression gene and can be used as a potential diagnostic biomarker of early-stage melanoma systemic spreading in blood.
Methods- Expression of FABP7 was assessed during melanoma progression through assessment of various clinicopathology stages of primary tumor progression and metastasis.
- FABP7 mRNA was highly expressed in 60 of 87 (69%) primary melanomas, compared with significant reduction in 13 of 68 (19%) metastatic melanomas.
- Analysis of 37 paired primary and metastatic melanomas by immunohistochemistry with anti-FABP7 Ab showed 73 and 27% positivity, respectively.
- FABP7 detection of metastatic tissues was inversely correlated with relapse-free and overall survival.
- To examine FABP7 expression loss in advanced melanomas, loss of heterozygosity (LOH) was assessed using microsatellite markers encompassing the FABP7 gene.
- LOH was identified in 10 of 20 (50%) metastatic melanomas at 6q22.31, compared with 0 of 14 primary melanomas.
- FABP7 as a surrogate biomarker for circulating tumor cells (CTCs) in blood was assessed by quantitative real-time (qRT)–PCR from melanoma pts' blood (n=134).
Related Articles
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma
Cancer, 10/30/09
Relevance Score: 69%
Analysis of Globule Types in Malignant Melanoma
Archives of Dermatology, 11/17/09
Relevance Score: 68%
Ground-glass nodules found in two patients with malignant melanomas: different growth rate and different histology
Clinical Imaging, 11/17/09
Relevance Score: 68%
Unusual variants of malignant melanoma
Clinics in Dermatology, 11/06/09
Relevance Score: 67%
Patterns of GRP78 and MTJ1 expression in primary cutaneous malignant melanoma
Modern Pathology, 10/23/09
Relevance Score: 67%
Today in Dermatologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
JWA regulates melanoma metastasis by integrin alphaVbeta3 signaling
Oncogene, 12/04/09
Immunocryosurgery for basal cell carcinoma: results of a pilot, prospective, open-label study of cryosurgery during continued imiquimod application
Journal of the European Academy of Dermatology and Venereology, 12/02/09
Self-reported screening for skin cancer in Austria
European Journal of Dermatology, 12/02/09
Sponsor
Article Search
Sponsor
Sponsor